Biosimilars developed by Celltrion and Samsung Bioepis have been expanding their presence in the domestic market. Samsung Bioepis' Onbevezy has surpassed sales of KRW 10 billion, becoming the top-selling biosimilar developed in South Korea. Since Q3 of last year, Celltrion's Remsima has allowed Onbevezy to take a market-leading position. However, it shows a rebound, with quarterly sales increasing to KRW 10 billion, reducing the gap with the market leaders.

According to the Financial Supervisory Service on December 5, domestic sales of Samsung Bioepis' Onbevezy increased by 12.9% year-over-year (YoY), with KRW 11.5 billion. Onbevezy has recorded the highest sales among domestically developed biosimilar pro